Connect your AI

Schrodinger SDGR Oncology, Neurology, and Immunology Product — Deferred Revenue

Other product segments

Software products and services

$6.2M-51.2%

Similar metrics at other companies

VCYTBiopharmaceutical and other revenue — Deferred Revenue

$700K-58.8%

ATENProducts — Deferred Revenue

$16.36M+205%

CIENProducts — Deferred Revenue

$31.65M0.0%

ARWRDeferred Revenue

$108.54M+151%

CYTKDeferred Revenue

$1.65M-96.8%

REGNDeferred Revenue

$636.2M+2.7%

Other financials

Income statement

Revenue$58.6M-1.6%

Gross profit$29.5M-5.1%

Operating income-$48.8M+4.1%

Net income-$60.0M-0.4%

EPS (diluted)-$0.81+1.2%

Balance sheet

Cash & equivalents$267.7M-20.7%

Total debt$107.0M-7.9%

Total equity$313.5M-16.1%

Total assets$634.2M-14.6%

Cash flow

Operating cash flow-$14.8M-110%

CapEx$2.5M+321%

Free cash flow-$17.3M-112%

Valuation

Market cap$1.15B-19.7%

Enterprise value$984.71M-18.3%

P/S4.5×-1.7×

Profitability

Gross margin55.3%-7.3pp

Operating margin-64.7%-12.0pp

Net margin-68.5%—

FCF margin9.6%+5.1pp

Returns & leverage

Return on equity-45.7%—

Debt / equity0.3×0.0×

Current ratio2.7×-0.7×

Where this comes from

Reported directly by Schrodinger in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiability.

The official record: Schrodinger’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Schrodinger's oncology, neurology, and immunology product — deferred revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Schrodinger's oncology, neurology, and immunology product — deferred revenue?: Schrodinger (SDGR) reported oncology, neurology, and immunology product — deferred revenue of $2.5M in Q1 2026.
What does oncology, neurology, and immunology product — deferred revenue mean?: The balance of payments received from customers for drug discovery services or collaborations that have not yet been recognized as revenue under accounting standards. It represents future revenue to be realized as performance obligations are satisfied over time.